Results 181 to 190 of about 1,425,532 (305)

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

Molecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal   +16 more
wiley   +1 more source

Multicentre dosimetry audit in the European randomized phase III study of neoadjuvant chemoradiotherapy using proton versus photon radiotherapy in locally advanced oesophageal cancer. [PDF]

Phys Imaging Radiat Oncol
Ehmsen ML, Byskov CS, Mortensen HR, Bütof R, Canters R, Defraene G, Haustermans K, Jensen MF, Meijers A, Muijs CT, Møller DS, Nordsmark M, Populaire P, Vilches-Freixas G, Nyvang L, Stolarczyk L, Makocki S, Broggi S, Fracchiolla F, Martignano A, Poels K, Rossomme S, Vasiliniuc S, Hoffmann L.   +23 more
europepmc   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

APECx-Anaesthesia, Perfusion and Surgical Practices in Cardiac Surgery: Main Study Protocol of a Modular Multiphase Prospective International Multicentre Observational Study. [PDF]

Acta Anaesthesiol Scand
Seegers JC, Grewal N, van Vliet R, Berger T, Bhatia B, Cozowicz C, Czerny M, D'Andria Ursoleo J, Corte AD, Dodic S, Fanning JP, Gasteiger L, Grewal S, Grønlykke L, Huhn R, Idhrees M, Itenov TS, Jassar AS, Ju JW, Karalapillai D, Kunst G, Lannemyr L, Lin DY, Mariani C, Martinsson A, McCabe E, Milne B, Monaco F, Møller-Sørensen PH, Neuner M, Pacini D, Perry LA, Raman J, Schmidt AF, Schoenhoff F, Segal R, Neto AS, Shook DC, Torregroza C, Vives M, Zochios V, van Meenen DMP, Beukers AM.   +42 more
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

European validation of the Barcelona magnetic resonance predictive model for significant prostate cancer detection in prostate biopsies. [PDF]

BJUI Compass
Morote J, Miró B, Regis L, Cousin F, Duflot P, Kolh P, Andalò A, Gentili N, Merloni F, Iamurri AP, Ferroni F, Trilla E, Méndez O.   +12 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Risk factors for COPD exacerbations and mortality, and variation between primary care settings: the PRAXIS cohort study in Sweden. [PDF]

Fam Med Community Health
Smith C, Hiyoshi A, Arnison T, Eliason G, Giezeman M, Hasselgren M, Janson C, Karlsson M, Kisiel MA, Lisspers K, Nager A, Sandelowsky H, Ställberg B, Sundh J, Montgomery S.   +14 more
europepmc   +1 more source

The Leprosy Study Centre in London [PDF]

Proceedings of the Royal Society of Medicine, 1977
openaire   +2 more sources

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source